Senseonics Holdings (SENS) Reports Q1 Loss of $0.15/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Senseonics Holdings, Inc. Reports First Quarter 2016 Financial Results
May 12, 2016 4:15 PM EDTGERMANTOWN, Md.--(BUSINESS WIRE)-- Senseonics Holdings, Inc. (NYSE-MKT: SENS), a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, today reported financial results for the first quarter ended March 31, 2016.
RECENT HIGHLIGHTS & ACCOMPLISHMENTS:
Initiated the multi-center PRECISE II pivotal clinical trial in the United States to demonstrate safety and effectiveness of the EversenseTM Continuous Glucose Monitoring System. Completed enrollment for the U.S. pivotal trial being conducted at 8 sites and including 90... More